This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT01262664 |
|---|---|
| Status | Terminated |
| Phase | Phase 1 |
| Sponsor | M.D. Anderson Cancer Center |
| Enrollment | 4 participants |
| Design | Interventional, Na, Single Group, Masking: None |
| Conditions | Prostate Cancer |
| Interventions | Prohibitin-TP01 |
| Start | May 24, 2012 |
| Primary completion | Jan 2, 2019 |
| Study completion | Jan 2, 2019 |
| Results posted | Not yet |
| Registry last updated | Jan 4, 2019 |
Compounds on this site that cite this trial
What the registry says the trial is about
The goal of this clinical research study is to find the highest tolerable dose of PROHIBITIN-TP01 that can be given to patients with advanced prostate cancer for which there are no standard therapy options. The safety of this drug will also be studied.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Acceptable Dose of Prohibitin-TP01 in Participants with Metastatic Prostate Cancer and Obesity | 58 days |
| Biologic Activity of Prohibitin-TP01 in Participants with Metastatic Prostate Cancer and Obesity | 28 days |
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
